Esperion Therapeutics CEO Koenig sells $69,546 in stock

CEO Sheldon L. Koenig sold 25,578 shares at $2.719 for $69,546 and now directly holds 2,172,699 Esperion shares. Q4 2025 EPS missed at $0.22 vs $0.29 expected while revenue of $168.45M rose 144% YoY and slightly beat estimates; InvestingPro forecasts FY2026 EPS of $0.09. Bempedoic acid earned multiple Class 1 recommendations in the 2026 ACC/AHA guidelines for statin-intolerant high-risk adults, and analyst views are mixed (H.C. Wainwright Buy PT $16; Citizens PT raised to $5; BofA Underperform PT $1.78); market cap ~$648M.

Analysis

The guideline upgrade is a structural demand catalyst that shifts prescribing from specialist-administered injectables toward an oral therapy that sits in primary care workflows, creating a multi-quarter uptake curve driven more by formulary and prior-authorization changes than by raw physician preference. That implies the fastest growth will come where payers adopt pathways quickly (large commercial plans, certain European markets) and the slowest where step-therapy or high rebate demands persist — expect heterogeneity across geographies and payers over a 3–12 month window.

Second-order winners include contract manufacturers and API suppliers that can scale oral cholesterol therapies quickly; second-order losers are high-priced injectables for the statin-intolerant niche whose volume and pricing leverage could be meaningfully eroded if oral alternatives gain formulary-favored status. Acquisition risk rises: a strategic buyer seeking an oral LDL-lowering franchise could accelerate international rollout, compressing time to peak sales from years to quarters and materially re-rating the asset if/when concrete deal chatter appears.

Key risks: durable margin expansion depends on negotiated net price and rebate dynamics rather than list price, so headline unit growth can translate to weak cash conversion if payers demand steep discounts. Near-term catalysts to watch are payer coverage policy releases, major MCO pathway updates, and the company’s next sales cadence — each can move consensus materially within 60–180 days and either validate the adoption thesis or expose fragility in the profitability forecast.

Contrarian read: the street seems to oscillate between bullish peak-case uptake and conservative pricing outcomes without anchoring to realistic payer timelines; that dichotomy creates a window to buy optionality rather than outright equity exposure. Staged, event-driven positions that monetize limited downside while keeping upside open capture the asymmetric payoff here better than an unhedged long or short.

Key Decisions for Investors

• Buy ESPR 12-month call spread (buy $3 / sell $8) sized to 1% NAV — defined max loss = premium; target payout ~3x if guidelines materially accelerate uptake across payers within 6–12 months. Cut losses if ESPR prints two consecutive quarters of negative net price realization or if broad payer coverage is denied.
• Long ESPR equity (0.5–1% NAV) paired with 3-month 25% OTM puts sized to cover 50% of position — timeframe 6–12 months. This preserves upside to guideline-driven adoption while capping short-term downside from headline execution or reimbursement shocks.
• Pair trade: long ESPR / short AMGN (notional ratio ~1:10 to remain market neutral) for 6–18 months — objective is to capture share displacement from high-cost injectables to an oral option. Tight stop if AMGN outperforms by >15% on biotech flow or if ESPR reports materially better-than-expected net pricing that implies broader market re-rating.
• Event watch: allocate a small buy option tranche (3–5% of position) ahead of major payer coverage announcements or the next sales update (expected within 60–180 days). Use realized volatility spike post-release as an opportunity to sell into strength or to tighten hedges.